Goodwin Advises Royalty Pharma on $511 Million Sale of Morphosys Development Funding Bonds
February 01, 2025
February 01, 2025
BOSTON, Massachusetts, Feb. 1 -- Goodwin, a law firm, issued the following news release:
The Life Sciences team advised Royalty Pharma plc (Nasdaq: RPRX) on the closing of a transaction to monetize the remaining fixed payments on the MorphoSys Development Funding Bonds for $511 million in upfront cash. This payment, combined with payments previously received, results in total cash proceeds of $530 million on the $300 million investment that was made in September 2022. The company ge . . .
The Life Sciences team advised Royalty Pharma plc (Nasdaq: RPRX) on the closing of a transaction to monetize the remaining fixed payments on the MorphoSys Development Funding Bonds for $511 million in upfront cash. This payment, combined with payments previously received, results in total cash proceeds of $530 million on the $300 million investment that was made in September 2022. The company ge . . .